AN Venture Partners to Host “S2S Japan 2025 Symposium” on November 13

Crystalys Therapeutics Advances Phase 3 Trials of Dotinurad for the Treatment of Gout with Dosing of First Patient

AN Venture Partner’s New Portfolio Company, Crystalys Therapeutics Launches with $205M Series A Financing to Advance Next-Generation Gout Treatment

AN Venture Partners Announces the Addition of Mikael Dolsten as Advisor

Pahr Therapeutics raises $14 million seed financing to pursue innovative treatments for Pulmonary Arterial Hypertension

AN Venture Partners Announces Final Close of $200M Fund I

AN Venture Partners Promotes Paula Schultheiss to Associate and Names Three New Fellows

City Therapeutics and Biogen Announce Strategic Research Collaboration to Develop Select Novel RNAi‑based Therapies

Typewriter Therapeutics Hires R&D Japan Head

AN Venture’s New Portfolio Company, Imbria Pharmaceuticals, Presents Positive Clinical Data in Patients in Cardiometabolic Heart Failure

AN Venture Partners Announce the Addition of Jun Hashimoto as Partner

Typewriter Therapeutics Selected for AMED’s Strengthening Program for Pharmaceutical Startup Ecosystem

AN Venture Partners Invests in City Therapeutics

AN Venture Partners Announces Two Strategic Hires

AN Venture Partners Strengthens Team with Appointment of Four Advisors

Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO

AN Ventures implements “Science2Startup (S2S) Japan” program

AN Venture Partners Selected as a Certified Venture Capital Provider for AMED’s Strengthening Program for Pharmaceutical Startup Ecosystem Initiative

Typewriter Therapeutics secures $5 million in financing; RA Capital Management and AN Ventures lead investor syndicate